

■ **The US National Institute of Allergies and Infectious Diseases has granted \$US10 million in funding to pharmaceutical company Baxter Healthcare to develop a vaccine against the coronavirus causing severe acute respiratory syndrome (SARS),* reports *Scrip*. Baxter will develop and produce an inactivated vaccine over the next 12–18 months for use in phase I/II trials by the US National Institutes of Health.**

* see Inpharma 1388: 3, 24 May 2003; 800888487

Baxter gets US funds for SARS vaccine. *Scrip* : 10, No. 2890, 3 Oct 2003 800943487